Erratum to “An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis” [Diab. Res. Clin. Pract. 135 (2018) 102–110]

We wish to acknowledge an error in our recent meta-analysis of the association of exposure to pioglitazone and bladder cancer [1]. After learning from Professor Azoulay that 10,951 patients (a figure not in the paper) were subsequently exposed to pioglitazone, his results [2] should have been included. The corrected hazard ratios (HRs) and numbers needed to treat for harm (NNTH) are shown in the Table. Although the additional study increases the HRs slightly making some of them statistically significant, the NNTH, i.e., one additional case of bladder cancer (1233 –4762) is far greater than the number needed to treat to benefit (NNTB) cardiovascular disease (13–256) and non-alcoholic steatohepatitis (3–12).
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Tags: Corrigendum Source Type: research